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OBJECTIVES We sought to evaluate the relation between stented segment length and restenosis.
BACKGROUND Multiple or long coronary stents are now being implanted in long lesions or in tandem lesions.
A longer stented segment might result in a higher probability of restenosis. However, there
is little information available on the relation between stented segment length and restenosis.
METHODS Between April 1995 and December 1996, 725 patients with 1,090 lesions underwent stenting.
Lesions were divided into three groups according to the length of the stented segment: 1)
group I (n 5 565): stented segment length #20 mm; 2) group II (n 5 278): stented segment
length .20 but #35 mm; and 3) group III (n 5 247): stented segment length .35 mm.
RESULTS There was no significant difference in the incidence of subacute stent thrombosis among the
three groups (0.4% in group I, 0.4% in group II, 1.2% in group III; p 5 NS). The minimal lumen
diameter (MLD) after stenting was greater in group I than in group III (3.04 6 0.60 mm in group
I, 3.01 6 0.54 mm in group II, 2.91 6 0.58 mm in group III; p , 0.05). At follow up, a smaller
MLD was observed in group III as compared with group I and group II (2.04 6 0.93 mm in
group I, 1.92 6 1.00 mm in group II, 1.47 6 0.97 mm in group III; p , 0.01). The restenosis
rates were 23.9% in group I, 34.6% in group II and 47.2% in group III (p , 0.01). Using
multivariate analysis, the longer stented segment, the angiographic reference vessel diameter and
the percent diameter stenosis after stenting were independent predictors of restenosis.
CONCLUSIONS The present study shows that a longer stented segment is an independent predictor of
restenosis without an influence on the risk of subacute thrombosis. (J Am Coll Cardiol 1999;
34:651–9) © 1999 by the American College of Cardiology
Coronary stenting has been shown to decrease the morbid-
ity of acute vessel closure (1). Although clinical and angio-
graphic restenosis rates in selected lesions are reduced with
coronary stenting as compared with angioplasty (2,3), it is
not known whether this benefit extends to other types of
lesions. Multiple or long coronary stents are now being
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implanted in long lesions or in tandem lesions. Previous
studies (4–7) have shown higher restenosis rates with
multiple overlapping stents. However, it is difficult to assess
the relative importance of increased metal exposure with
multiple partial overlapping stents versus a long lesion or a
long stented segment. A longer stented segment might
result in a higher probability of restenosis. However, there is
little information on the relation between stented segment
length and restenosis.
METHODS
Study patients. Between April 1995 and December 1996,
754 consecutive patients with 1,119 lesions underwent
intracoronary stenting at Centro Cuore Columbus in Milan,
Italy. In 29 lesions, another stent was deployed in the first
stent because of plaque prolapse. These lesions with almost
completely overlapping stents were excluded from further
analysis. A total of 1,090 lesions in 725 patients were
included in this study. Lesions were divided into three
groups according to the length of the stented segment: 1)
group I (n 5 565): stented segment length #20 mm; 2)
group II (n 5 278): stented segment length .20 but
#35 mm; and 3) group III (n 5 247): stented segment
length .35 mm. Of 1,090 lesions, 277 were treated with
multiple stents. Because the operator tried to deploy mul-
tiple stents with minimal or no overlap, the length of the
stented segment for these lesions was considered as the sum
of the length of implanted stents.
Stent implantation procedure. Procedural details of stent
placement have been described previously (8–10). Indica-
tions for stenting were defined as follows: elective stenting
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was performed when the operator elected to use stenting
before starting the procedure. Suboptimal result stenting
was defined as insertion of a stent for a focal dissection or
significant vascular recoil after percutaneous transluminal
coronary angioplasty (PTCA) associated with .30% lumen
narrowing without ischemia. Threatened closure stenting
was performed when PTCA was complicated by a longitu-
dinal or a spiral dissection associated with .50% lumen
encroachment (ischemia was not always present in the
setting of threatened closure). Acute occlusion stenting was
undertaken to relieve ischemia associated with total or
subtotal vessel closure after angioplasty with no or markedly
delayed distal flow (Thrombolysis in Myocardial Infarction
[TIMI] flow grade 0 or 1). Total occlusion stenting was
performed after reopening a vessel that had been occluded
before the procedure had begun. Restenosis stenting was
performed for lesions with a history of restenosis after one
or more previous angioplasty procedures.
The following stents were used: the Palmaz-Schatz stent
(Johnson & Johnson Interventional Systems, Warren, New
Jersey), the Gianturco-Roubin stent (Cook, Bloomington,
Indiana), the Wiktor stent (Medtronic Interventional Vas-
cular, Kerkrade, The Netherlands), the AVE Micro stent
(Arterial Vascular Engineering, Santa Rosa, California), the
Cordis stent (Cordis, Miami, Florida), the Wallstent
(Schneider-Europe, Bulach, Switzerland), the Angiostent
(AngioDynamics, Glens Falls, New York), the NIR stent
(Medinol, Tel Aviv, Israel), the Multi Link stent (Advanced
Cardiovascular Systems, Santa Clara, California), the
Crown stent (Johnson & Johnson Interventional Systems),
the beStent (Medtronic In Stent, Minneapolis, Minnesota),
the ACT-One nitinol stent (Progressive Angioplasty Sys-
tems, Menlo Park, California), the Tensum Biotronik stent
(Biotronik, Berlin, Germany), the Div Ysio stent (Biocom-
patibles, Galway, Ireland), the PURA VARIO stent (DEV-
ON Medical, Hamburg, Germany) and the IRIS stent
(UNI-CATH, Saddle Brook, New Jersey). Stenting of a
lesion with two or more kinds of stents was defined as
combination of stents.
After stent implantation, angiographic optimization was
performed using high pressure balloon dilation to achieve an
acceptable angiographic result with ,20% residual stenosis
by visual estimate. In some of the lesions intravascular
ultrasound (IVUS) was used at the operator’s discretion.
Subsequent treatment decisions were based on IVUS results
in conjunction with angiographic assessment. The final
IVUS evaluation was the IVUS study after the last balloon
inflation that documented achievement of optimal stent
expansion criteria (8).
Before stent implantation, patients received aspirin
(325 mg/day), which was continued indefinitely. After stent
implantation, ticlopidine (250 mg two times a day) was
added for one month. In rare situations oral anticoagulation
was added without the use of ticlopidine.
Procedure success was defined as a final angiographic
residual diameter stenosis ,30% by quantitative analysis
without a major complication (death, Q wave myocardial
infarction or coronary artery bypass graft surgery) during the
hospital period. Q wave myocardial infarction was docu-
mented by the presence of new Q waves of at least 0.04 in
duration and a creatine kinase level or MB fraction at least
twice the upper limit of normal. Acute thrombosis events
were defined as angiographically documented occlusion
with TIMI flow grade 0 or 1 at the stent site occurring
within 24 h of the stent procedure. Subacute thrombosis
events were angiographically documented occlusions with
TIMI flow grade 0 or 1 at the stent site occurring beyond
24 h and within the first month of the stent procedure.
Quantitative coronary angiography. Patients received in-
tracoronary nitroglycerin before initial, final and follow-up
angiograms to achieve maximal vasodilation. Quantitative
analysis was performed as previously described using an
automated computer-based system by experienced angiog-
raphers not involved in the stenting procedure (11). Image
calibration was performed with a contrast-filled catheter.
The external diameter of the catheter was used as the
calibration standard. Coronary end-diastolic frames from
matched views obtained on initial, final and follow-up
angiograms were analyzed using a contour detection mini-
mal cost algorithm (QCA-CMS version 3.0, MEDIS,
Leiden, The Netherlands). Reference and minimal lumen
diameters (MLD) were determined from the single worst
view. In some of the lesions with total occlusion, lesion
length could not be measured before the intervention, and it
was therefore measured after dilation with a small (1.5 or
2 mm) balloon catheter. Lesions were characterized accord-
ing to the modified American College of Cardiology/
American Heart Association (ACC/AHA) classification
(12). Acute lumen gain was defined as the difference
between the MLD before and after the intervention. Late
lumen loss was defined as the difference between the MLD
immediately after the intervention and at follow-up angiog-
raphy. The loss index was calculated as the ratio of the late
lumen loss to the acute lumen gain. Restenosis was defined
as diameter stenosis $50% at follow-up angiography.
Intravascular ultrasound equipment and measurements.
Intravascular ultrasound studies were performed using the
Cardiovascular Imaging System (CVIS, Sunnyvale, Califor-
nia). This system uses a single-element 30-MHz beveled
transducer within either a 2.9F long or a 3.2F short
Abbreviations and Acronyms
ACC/AHA 5 American College of
Cardiology/American Heart Association
IVUS 5 intravascular ultrasound
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
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monorail imaging catheter. The transducer was withdrawn
automatically at 0.5 mm/s to perform the imaging sequence.
The position of the catheter on fluoroscopy was used to
correlate the ultrasound image with the angiogram. The
ultrasound catheter was advanced distal to the stent, and
images were recorded while the imaging catheter was pulled
back. On-line quantitative measurements were performed
during the procedure. Intravascular ultrasound studies were
recorded on 1⁄2-in. high resolution s-VHS tape for off-line
analysis.
The major and minor diameters of the lumen and vessel
were measured. Lumen and vessel cross-sectional areas were
planimetered at the lumen–intima interface and the media–
adventitia interface, respectively. The part of the lesion with
the smallest lumen area was selected for measurements for
each pass of the IVUS catheter. Reference lumen cross-
sectional areas were measured proximal and distal to the
stented segments in the closest most normal-appearing
segments.
Statistical analysis. Data were expressed as proportions or
mean value 6 SD. Differences in categoric variables were
analyzed using the chi-square test, and differences in con-
tinuous variables were analyzed using analysis of variance.
The Scheffe´ F test was used as a post hoc test when analysis
of variance was done. Statistical significance was defined as
p , 0.05.
Univariate analysis consisted of the chi-square test for
categoric variables and an unpaired, two-tailed t test for
continuous data. The variables that were found to be
significant by univariate analysis were entered into multi-
variate analysis. The independent association of several
variables with restenosis was evaluated using forward step-
wise logistic regression analysis with the statistical computer
package SPSS (SPSS, Inc., Chicago, Illinois). Forward
stepwise procedures were used with a cutoff p value of 0.05
for inclusion of variables in the model, maintaining those
variables with a Wald Static significance ,0.1.
RESULTS
Patient characteristics. The clinical characteristics of the
patients are shown in Table 1. There were no differences in
terms of age; gender; incidences of risk factors, previous
angioplasty, unstable angina and multivessel disease; left
ventricular ejection fraction; and use of anticoagulation or
antiplatelet therapy among the three groups. Group III had
a higher incidence of previous myocardial infarction and a
lower incidence of previous coronary artery bypass graft
surgery than the other groups.
Angiographic and procedural characteristics. The indi-
cation for stenting and angiographic characteristics are
shown in Table 2. Group III had a lower frequency of
elective stenting and a higher frequency of total occlusion
stenting than groups I and II. Stent implantation was
performed more frequently in the left circumflex artery and
less frequently in the left anterior descending coronary
artery or the right coronary artery in group I as compared
with groups II and III. The proximal location site and type
B2 lesion (according to the modified AHA/ACC classifi-
cation) were most frequent in groups I and II, whereas the
mid-lesion site and type C lesion were most frequent in
group III.
Table 1. Patient Characteristics
Group I
(n 5 565)
Group II
(n 5 278)
Group III
(n 5 247) p Value
Age (yr) 59 6 10 59 6 10 59 6 11 NS
Male (%) 90 87 86 NS
Risk factors
Hypertension 49 45 50 NS
Hypercholesterolemia 57 58 55 NS
Diabetes 12 15 13 NS
Current smoker 27 24 23 NS
Family history 45 45 47 NS
Previous MI 53 53 62 , 0.05
Previous PTCA 12 14 7 NS
Previous CABG 13 13 6 , 0.05
LVEF 60 6 11% 59 6 11% 58 6 11% NS
Unstable angina 26 28 28 NS
Multivessel disease 69 73 72 NS
Anticoagulant therapy 0.4 0.4 1 NS
Antiplatelet therapy NS
Ticlopidine 1 aspirin 93 95 94
Aspirin alone 7 5 6
Data are presented as mean value 6 SD or percentage.
CABG 5 coronary artery bypass graft surgery; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction;
PTCA 5 percutaneous transluminal coronary angioplasty.
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The procedural characteristics are shown in Table 3. The
implanted stents were different among the three groups.
The Palmaz-Schatz stent and the NIR stent were deployed
more frequently in groups I and II. In contrast, a combina-
tion of different stents, the Wallstent and the Gianturco-
Roubin stent were used more frequently in group III. The
number of stents used was higher in groups II and III than
in group I. A single stent was implanted in almost all lesions
Table 2. Indication for Stenting and Angiographic Characteristics
Group I
(n 5 565)
Group II
(n 5 278)
Group III
(n 5 247)
p
Value
Indication for stenting (%) , 0.01
Elective 71 68 58
Restenosis 9 8 4
Suboptimal result 7 7 9
Threatened vessel closure 6 7 9
Acute vessel closure 1 1 2
Total occlusion 7 10 19
Stented vessel (%) , 0.01
LAD 41 49 46
RCA 25 31 36
LCx 28 17 17
LMCA 3 1 0
Vein graft 3 2 2
Lesion site (%) , 0.01
Ostial 12 5 3
Proximal 39 43 36
Midvessel 34 40 52
Distal 16 12 8
Modified AHA/ACC lesion type (%) , 0.01
A 3 2 1
B1 34 26 13
B2 46 48 42
C 17 25 44
AHA/ACC 5 American Heart Association/American College of Cardiology; LAD 5 left anterior descending coronary artery;
LCx 5 left circumflex artery; LMCA 5 left main coronary artery; RCA 5 right coronary artery.
Table 3. Procedural Characteristics
Group I
(n 5 565)
Group II
(n 5 278)
Group III
(n 5 247)
p
Value
Type of stent (%) , 0.01
Palmaz-Schatz stent 40 15 9
Gianturco-Roubin stent 7 0 17
AVE Micro stent 10 10 12
Wallstent 1 6 18
NIR stent 21 30 8
Crown stent 2 13 2
beStent 5 12 2
Other stents* 14 9 3
Combination of stents 0 5 29
Stents/lesion 1.0 6 0.1 1.4 6 0.5 2.2 6 1.2 , 0.01
Multiple stents (%) 2 42 56 , 0.01
Length of stents (mm) 15 6 3 30 6 3 52 6 16 , 0.01
Final balloon size (mm) 3.50 6 0.48 3.57 6 0.47 3.60 6 0.50 , 0.05
Final B/V ratio† 1.18 6 0.18 1.22 6 0.19 1.25 6 0.20 , 0.01
Maximal inflation pressure (atm) 16.7 6 3.5 16.8 6 3.2 16.7 6 3.4 NS
Data are presented as mean value 6 SD or percentage.
*Other stents include the Wiktor stent, the Cordis stent, the Angiostent, the Multi Link stent, the ACT-One nitinol stent,
the Tensum Biotronik stent, the Div Ysio stent, the PURA VARIO stent and the IRIS stent. †The balloon diameter used to
calculate this ratio was the nominal size of each individual balloon. B/V 5 balloon-vessel ratio.
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in group I, whereas multiple stents were deployed in almost
half of the lesions in groups II and III. By definition, there
was a significant difference in the length of the stented
segment among the three groups. The final balloon size was
greater in group III than in group I. The balloon vessel ratio
was higher in groups II and III than in group I. There was
no significant difference in maximal inflation pressure
among the three groups.
Procedural outcomes. The procedural outcomes are
shown in Table 4. There were no significant differences in
the incidences of angiographic success, procedural myocar-
dial infarction and procedural death. The incidence of
procedural coronary artery bypass graft surgery was higher in
group III than in groups I and II. Procedural success was
lower in group III than in groups I and II.
Acute stent thrombosis occurred more frequently in
group III than in groups I and II. However, in lesions
without acute or threatened closure, it was not different
among the three groups (0.2% in group I, 0% in group II,
0.5% in group III). There was no significant difference in
the incidence of subacute stent thrombosis among the three
groups.
Quantitative angiographic analysis. Table 5 shows the
results of quantitative angiographic analysis. There were no
significant differences in the reference vessel diameter at
baseline, after stenting and at follow up among the three
groups. Group III had a smaller MLD and a higher percent
diameter stenosis at baseline than did groups I and II. The
lesion length was longer in groups II and III than in group
I. The MLD after stenting was greater in group I than in
group III. After stenting group III had a greater residual
percent diameter stenosis than did groups I and II.
Of the 1,040 lesions eligible for follow up, 743 (71%) had
follow-up angiography at 5.4 6 1.9 months after stent
implantation. At follow up, a smaller MLD and a higher
percent diameter stenosis were observed in group III than in
groups I and II. Groups II and III had a longer lesion length
at follow up than did group I. Although there was no
significant difference in acute lumen gain among the three
groups, group III had greater late lumen loss than did
groups I and II. The loss index was greater in group III than
in group I. The restenosis rates were 23.9% in group I,
34.6% in group II and 47.2% in group III (p , 0.01, Fig.
1A). To exclude the potential effect of multiple overlapping
stents, the restenosis rates in the lesions with a single stent
were also investigated (24.3% in group I, 41.8% in group II
and 41.4% in group III [p , 0.01]) (Fig. 1B). The
restenosis rates in the lesions with slotted tube stents were
Table 4. Procedural Outcomes and Clinical Events
Group I
(n 5 565)
Group II
(n 5 278)
Group III
(n 5 247)
p
Value
Procedural success 96 98 92 , 0.01
Angiographic
success
99 99 98 NS
Procedural MI 2.3 1.4 3.2 NS
Procedural CABG 0.4 0.3 2.4 , 0.01
Procedural death 0 0 0 NS
Acute thrombosis 0.2 0 1.2 , 0.05
Subacute thrombosis 0.4 0.4 1.2 NS
Data are presented as percentages.
CABG 5 coronary artery bypass graft surgery; MI 5 myocardial infarction.
Table 5. Quantitative Angiographic Results
Group I
(n 5 565)
Group II
(n 5 278)
Group III
(n 5 247) p Value
Before procedure
RVD (mm) 3.03 6 0.55 2.96 6 0.50 2.95 6 0.55 NS
MLD (mm) 0.88 6 0.48 0.84 6 0.43 0.72 6 0.48 , 0.01
Percent stenosis 71 6 14 72 6 13 76 6 15 , 0.01
Lesion length (mm) 9.5 6 5.2 12.4 6 7.4 13.5 6 8.4 , 0.01
After stenting
RVD (mm) 3.17 6 0.56 3.19 6 0.48 3.17 6 0.53 NS
MLD (mm) 3.04 6 0.60 3.01 6 0.54 2.91 6 0.58 , 0.05
Percent stenosis 4 6 11 5 6 12 8 6 12 , 0.01
Angiographic follow-up (%) 69 70 78 , 0.05
At follow-up
RVD (mm) 3.03 6 0.53 3.05 6 0.53 2.94 6 0.58 NS
MLD (mm) 2.04 6 0.93 1.92 6 1.00 1.47 6 0.97 , 0.01
Percent stenosis 34 6 26 39 6 26 52 6 29 , 0.01
Lesion length (mm) 7.0 6 5.9 8.7 6 7.6 10.5 6 7.9 , 0.01
Acute lumen gain (mm) 2.16 6 0.63 2.16 6 0.61 2.19 6 0.69 NS
Late lumen loss (mm) 1.01 6 0.87 1.07 6 0.90 1.41 6 0.86 , 0.01
Loss index 0.48 6 0.46 0.56 6 0.45 0.68 6 0.49 , 0.05
Data are presented as mean value 6 SD or percentage.
MLD 5 minimal lumen diameter; RVD 5 reference vessel diameter.
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evaluated because the effect on restenosis may be different
between slotted tube stents and coil stents (21.8% in group
I, 35.5% in group II and 45.0% in group III [p , 0.01])
(Fig. 1C). Because stenting for total occlusion was frequent
in group III, the restenosis rates in the lesions without total
or subtotal occlusion before the procedure were evaluated
(22.7% in group I, 33.9% in group II and 49.3% in group III
[p , 0.01]) (Fig. 1D). To exclude the potential effect of
acute or threatened closure, restenosis rates in lesions
without acute or threatened closure after PTCA were
evaluated (23.9% in group I, 33.3% in group II and 45.1%
in group III [p , 0.01]) (Fig. 1E). The restenosis rates in
lesions with IVUS optimization were evaluated because
IVUS optimization may affect restenosis (19.9% in group I,
27.4% in group II and 41.2% in group III [p , 0.01]) (Fig.
1F).
Intravascular ultrasound analysis. Intravascular ultra-
sound measurements after stenting are shown in Table 6.
These measurements after the stent procedure were avail-
able in 546 (50%) of the 1,090 lesions. There were no
significant differences in the proximal reference vessel di-
ameter and cross-sectional area among the three groups.
Group III had a smaller MLD in the stented segment than
did group I. The minimal lumen cross-sectional area in the
stented segment was smaller in group III than in groups I
and II. The distal reference vessel diameter and lumen
cross-sectional area were smaller in group III than in groups
I and II.
Multivariate analysis. Table 7 shows the results of univar-
iate and multivariate analysis. When the variables that were
significant by univariate analysis were entered into forward
stepwise logistic regression analysis, three factors were
independent predictors of restenosis: length of the stented
segment, angiographic reference vessel diameter and percent
diameter stenosis after stenting.
DISCUSSION
The present study shows that a progressively longer stented
segment is associated with an increased risk of restenosis,
but does not influence the risk of subacute thrombosis.
Figure 1. Restenosis rates after stenting in all lesions (A). Subgroup analysis in lesions with a single stent (B), those with slotted tube stents
(C), those without total or subtotal occlusion before the procedure (D), those without acute or threatened closure after PTCA (E) and
those with IVUS optimization (F).
Table 6. Final Intracoronary Ultrasound Results
Group I
(n 5 258)
Group II
(n 5 159)
Group III
(n 5 129)
p
Value
Proximal reference
LD (mm) 3.2 6 0.6 3.3 6 0.6 3.2 6 0.6 NS
LCSA (mm2) 9.4 6 3.4 9.9 6 3.3 9.9 6 4.2 NS
Stented segment
MLD (mm) 2.9 6 0.5 2.8 6 0.4 2.7 6 0.4 , 0.01
MLCSA (mm2) 7.5 6 2.4 7.3 6 2.1 6.6 6 2.1 , 0.01
Distal reference
LD (mm) 2.9 6 0.6 2.9 6 0.5 2.7 6 0.5 , 0.01
LCSA (mm2) 7.8 6 3.2 7.5 6 3.0 6.6 6 2.9 , 0.01
Data are presented as mean value 6 SD.
LCSA 5 lumen cross-sectional area; LD 5 lumen diameter; MLCSA 5 minimal
lumen cross-sectional area; MLD 5 minimal lumen diameter.
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Multivariate analysis shows that a longer stented segment,
as well as the angiographic reference vessel diameter and
percent diameter stenosis after stenting, are independent
predictors of restenosis.
Restenosis in the lesion with a long stented segment.
The influence of lesion length on restenosis after stenting is
controversial. Schomig et al. (13) showed that lesion length
was an independent correlate of the amount of late lumen
loss. In contrast, other studies (4,5) did not demonstrate the
relation between lesion length and restenosis. However,
previous studies (4–7) have shown higher rates of restenosis
with multiple stents as compared with a single stent. After
implantation of Palmaz-Schatz stents, Ellis et al. (4) found
a 64% incidence of restenosis at sites where multiple
overlapping stents were placed. The higher restenosis rate
was explained by greater metal density with multiple over-
lapping stents, which results in more pronounced neointi-
mal hyperplasia (14–17). However, most of the previous
studies (4,6,7) that investigated the relation between lesion
length, multiple overlapping stents and restenosis were
performed with multiple Palmaz-Schatz stents. Because the
length of a Palmaz-Schatz stent is 15 mm, it is difficult to
assess the relative importance of increased metal exposure
with multiple partial overlapping stents versus a long lesion
Table 7. Predictors of Restenosis
No Restenosis
at Follow-Up
(n 5 504)
Restenosis
at Follow-Up
(n 5 239)
Univariate
p Value
Multivariate
p Value
Clinical factors
Age (yr) 58 6 10 59 6 11 NS —
Male (%) 86 85 NS —
Hypertension (%) 48 45 NS —
Hypercholesterolemia (%) 58 58 NS —
Diabetes (%) 12 16 NS —
Current smoker (%) 27 21 NS —
Family history (%) 50 48 NS —
Previous MI (%) 56 54 NS —
Previous angioplasty (%) 9 13 NS —
LVEF (%) 60 6 11 59 6 12 NS —
Unstable angina (%) 26 33 NS —
Multivessel disease (%) 70 76 NS —
Angiographic characteristics
Vessel distribution (%) , 0.05 NS
LAD 49 41
RCA 25 35
LCx 23 22
LMCA 2 0.4
Vein graft 2 3
Modified AHA/ACC lesion type
B2 or C (%) 71 73 NS —
Procedural factors
Maximal inflation pressure (atm) 16.9 6 3.4 16.5 6 3.3 NS —
Final balloon/vessel ratio* 1.18 6 0.16 1.21 6 0.20 NS —
Stented segment length (mm) 25.1 6 14.8 32.8 6 19.9 , 0.001 , 0.001
Multiple stenting (%) 22 29 , 0.05 NS
Acute stenting (%) 6 9 NS —
Coil stent (%)† 11 18 , 0.01 NS
Combination of stents (%) 7 14 , 0.01 NS
QCA measurement
Baseline reference diameter (mm) 3.09 6 0.52 2.79 6 0.51 , 0.001 , 0.001
Baseline MLD (mm) 0.87 6 0.49 0.76 6 0.44 , 0.01 NS
Baseline percent stenosis 72 6 14 73 6 15 NS —
Lesion length (mm) 12.0 6 7.3 14.1 6 8.2 , 0.05 NS
Final MLD (mm) 3.10 6 0.56 2.86 6 0.51 , 0.001 NS
Final percent stenosis 4 6 10 6 6 11 , 0.01 , 0.05
Data are presented as mean value 6 SD or percentage.
*The balloon diameter used to calculate this ratio was the nominal size of each individual balloon. †Combination of slotted
tube stent and coil stent was included.
QCA 5 quantitative coronary angiography; MLD 5 minimal lumen diameter; see Tables 1 and 2 for other abbreviations.
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or a long stented segment. The availability of long stents
enables one to evaluate outcome without the confounding
factors of stent overlapping or stent gaps. The present study
shows a persistently higher restenosis rate for the lesions
treated with a single long stent as compared with a single
short stent (Fig. 1B). The results of multivariate analysis
demonstrate that the length of the stented segment is an
independent predictor of restenosis, although multiple
stents are not predictive. Strauss et al. (5) showed that after
implantation of Wallstents, there was no relation between
stent length and restenosis, although multiple overlapping
stents was a predictor of restenosis. However, the specific
nature of self-expanding stents may be unique and not
comparable with other experiences.
The high restenosis rate seen with multiple stents as well
as with long stents supports the view that the problem may
be difficult to solve with a mechanical approach. When
stenting a long lesion with a long stent, a number of
variables that are likely to affect the outcome come into play.
The two most important ones are the higher probability for
an unfavorable metal to artery interaction as more artery is
exposed to metal, and the natural vessel tapering invariably
associated with stenting a long segment. The latter factor
adds a smaller reference vessel size and a smaller achievable
final stent lumen, which are known factors associated with
increased risk of restenosis (2,18).
Subacute thrombosis in the lesion with a long stented
segment. Subacute stent thrombosis is one of the most
feared complications after stenting, resulting in ischemic
complications such as death and myocardial infarction. A
low incidence of subacute thrombosis has been reported
after high pressure final balloon dilation and the use of
antiplatelet therapy with ticlopidine and aspirin without
anticoagulation (8,19,20). However, there have been fears
that the risk of thrombosis might increase with exposure of
more metal after longer or multiple stent implantation. In
fact, a previous study (21) showed that the use of multiple
stents was one of the predictors of subacute thrombosis. In
contrast, other studies demonstrated low incidences of
subacute thrombosis with multiple stents (7,22). The
present study supports the view that a long stented segment
is not associated with an increased risk of subacute throm-
bosis when a good initial result is obtained. Most of the
patients underwent optimization of stent deployment with
high pressure balloon dilation, had dissection sites appro-
priately covered and received antiplatelet therapy with
ticlopidine and aspirin without anticoagulation. These fac-
tors probably played a significant role in maintaining a low
incidence of subacute thrombosis in the present study.
In contrast to subacute thrombosis, the incidence of acute
thrombosis was higher in patients with a longer stented
segment. However, in lesions without acute or threatened
closure, it was not different among the three groups.
Patients with a longer stented segment should be observed
carefully for a period of 24 h after the procedure if stenting
was performed in lesions with acute or threatened closure
after PTCA.
Study limitations. This is a retrospective study, which
accounts for the differences in patient backgrounds among
the three groups. During the study period (1995–1996),
there was some evolution of the stenting procedure, and
changes in decision-making occurred. Although we tried to
deploy multiple stents with minimal or no overlap, the
length of a stented segment with multiple stents may be
slightly overestimated. However, the restenosis rate was
higher in the lesions with a longer single stent. Another
possible limitation is that many different types of stents were
used in the study. Restenosis rates in the lesions with
different types of stents may vary, however. In the subgroup
analysis using only slotted tube stents, for example, resten-
osis rates were still higher in lesions with a longer stented
segment. The next possible confounding variable was stent-
ing for total occlusions, which was more frequent in group
III than in groups I or II. Subanalysis eliminating this group
from the calculations showed that restenosis rates continued
to be higher in the lesions with a longer stented segment.
There was a discrepancy between lesion length and
stented segment length. In most of the lesions, stented
segment length was longer than lesion length (Fig. 2),
although there was a significant correlation between lesion
length and stented segment length (p , 0.01). In the
present study, IVUS was used in half of all the lesions
included in all three groups. Using IVUS, Mintz et al. (23)
showed that atherosclerosis was ubiquitous in angiographi-
cally normal coronary artery reference segments. If lesion
length was measured with IVUS, it would be longer than
that measured by angiography. Therefore, stented segment
length might be much longer than lesion length as measured
by angiography, especially in cases where IVUS was used. In
the First International New Intravascular Rigid-Flex Endo-
vascular Stent Study (FINESS) (24), although only 6% of
lesions were assessed to be .15 mm in length by quantita-
tive angiography, experienced operators chose a long
(32 mm) NIR stent for 26% of the NIR stents that were
deployed. They explained that this choice might reflect a
Figure 2. The relation between stented segment length and lesion
length. There was a significant correlation between lesion length
and stented segment length (p , 0.01). In most of the lesions,
stented segment length was longer than lesion length (above
dashed line).
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desire by the interventionalist to more completely cover
visible vessel narrowing beyond the area of significant
stenosis or to treat consecutive lesions with a single stent.
We believe that is an issue that also played some significant
role in the present study. In addition, in lesions with
dissection after PTCA, stented segment length might be
longer than lesion length.
This study represents a relatively large, nonselected,
single-center experience, which provides some insight into
the difficulties associated with use of long stent lengths, and
how this is a strong independent predictor of restenosis.
Conclusions. Even when possible confounding variables
are removed, a longer stented segment remains a strong
independent predictor of restenosis without influencing the
risk of subacute thrombosis. Therefore, when stenting is
performed, the shortest possible stent length should be used.
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